{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:53:05Z","timestamp":1789084385701,"version":"build-2803163510"},"reference-count":22,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>There are limited data regarding the impact of disease-related complications on the survival of multiple myeloma (MM) patients. The primary objective of this study was to determine the prevalence of disease-related complications, including hypercalcemia, renal insufficiency, anemia, and bone lytic lesions in MM patients. The secondary objectives were to determine clinical characteristics, treatment outcomes, and the association of disease-related complications and mortality. A retrospective chart review of MM patients from November 2014 to December 2019 was conducted. A total of 200 MM patients were enrolled. The median age at diagnosis was 63 years. The bone lytic lesion was the most common disease-related complication found in 85% during first-line therapy, followed by anemia (71.5%), renal insufficiency (28.5%), and hypercalcemia (20%). While anemia was the most common complication during the second (51.2%) and third-line therapy (72%). The development of skeletal-related events (SREs) after treatment is a disease-related complication that is associated with decreased overall survival (HR 4.030, 95% CI 1.97\u20138.24, p &lt; 0.001). The most common disease-related complication of MM at initial diagnosis is bone lytic lesions, whereas anemia is more common with subsequent relapses. The presence of SRE after treatment is associated with the increased mortality of MM patients.<\/jats:p>","DOI":"10.3390\/hematolrep16010009","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T06:50:22Z","timestamp":1708498222000},"page":"89-97","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prevalence, Outcomes and Impact of Disease-Related Complications in the Survival of Multiple Myeloma Patients"],"prefix":"10.3390","volume":"16","author":[{"given":"Wachiralak","family":"Tothong","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adisak","family":"Tantiworawit","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalita","family":"Norasetthada","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chatree","family":"Chai-Adisaksopha","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teerachat","family":"Punnachet","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonthakorn","family":"Hantrakun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9730-8260","authenticated-orcid":false,"given":"Pokpong","family":"Piriyakhuntorn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanawat","family":"Rattanathammethee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1248-9734","authenticated-orcid":false,"given":"Sasinee","family":"Hantrakool","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7819-5544","authenticated-orcid":false,"given":"Ekarat","family":"Rattarittamrong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3324\/haematol.2017.178103","article-title":"Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry","volume":"103","author":"Blimark","year":"2018","journal-title":"Haematologica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100215","DOI":"10.1016\/j.jbo.2018.100215","article-title":"Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data","volume":"14","author":"Kim","year":"2019","journal-title":"J. Bone Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.2019.230011","article-title":"Fractures and survival in multiple myeloma: Results from a population-based study","volume":"105","author":"Thorsteinsdottir","year":"2020","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/ar2168","article-title":"Multiple myeloma\/hypercalcemia","volume":"9","author":"Oyajobi","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajh.23731","article-title":"Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study","volume":"89","author":"Kim","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk-stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/17474086.2018.1537776","article-title":"Prognostic factors for multiple myeloma in the era of novel therapies","volume":"11","author":"Ziogas","year":"2018","journal-title":"Expert. Rev. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for Multiple Myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","article-title":"Renal failure in multiple myeloma: Reversibility and impact on the prognosis","volume":"65","author":"Knudsen","year":"2000","journal-title":"Eur. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","article-title":"Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review","volume":"91","author":"Caro","year":"2001","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3324\/haematol.2022.280893","article-title":"Thrombosis in multiple myeloma: Risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel","volume":"107","author":"Larocca","year":"2022","journal-title":"Haematologica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: A population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/16\/1\/9\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:02:02Z","timestamp":1760104922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/16\/1\/9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["hematolrep16010009"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep16010009","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]}}}